Woodroww - i'm on the subscription email list - hence it wasn't posted to the website yet - but should be by Monday as noted in the email. You can join it for free if you like - i'll cut and paste some of the excerpts b/c the profile posted has a lot of info - GLTY! Partial email posted:
ACTC
The company is in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases. The Company noted that in the next few weeks, it will be completing the preclinical work necessary for filing the IND. To date, no adverse events have occurred in testing. The results will be part of the submission which Advanced Cell expects to submit to the FDA prior to the end of the year.
"We are very pleased with the long-term safety and efficacy data," said Dr. Robert Lanza, ACT's Chief Scientific Officer. "We have carried out pre-clinical studies using these cells in multiple animal models, and to-date have not seen any teratoma formation or untoward pathological reactions. We are optimistic that human embryonic stem cells (hESCs) will serve as a potentially safe and inexhaustible source of RPE for the treatment of a range of macular degenerative diseases."